ArticleYonsei medical journal2022

Short-Term Outcomes of the First in Vivo Gene Therapy for RPE65-Mediated Retinitis Pigmentosa.

Jay Jiyong Kwak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.